KPC Pharmaceuticals Inc (600422.SS)

600422.SS on Shanghai Stock Exchange

12:29pm IST
Change (% chg)

¥-0.22 (-2.19%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Chart for


KPC Pharmaceuticals, Inc. is a China-based company principally engaged in the research and development, manufacturing and sales of pharmaceuticals. The Company's main products include natural herbal medicines, traditional Chinese medicines and chemical synthetic drugs, such as central nervous system drugs, cardiovascular and... (more)


Beta: 0.72
Market Cap(Mil.): ¥9,322.30
Shares Outstanding(Mil.): 788.69
Dividend: 0.18
Yield (%): 1.52


  600422.SS Industry Sector
P/E (TTM): 24.90 30.94 32.74
EPS (TTM): 0.47 -- --
ROI: 9.51 14.83 14.37
ROE: 10.67 16.33 16.07

BRIEF-KPC Pharmaceuticals Plans Share BuyBack Worth 200-500 Million Yuan Within Six Months

* SAYS IT PLANS TO BUY BACK COMPANY SHARES WORTH 200-500 MILLION YUAN AT NO HIGHER THAN 11 YUAN ($1.73) PER SHARE WITHIN SIX MONTHS Source text in Chinese: http://bit.ly/2CcjHQG Further company coverage: ($1 = 6.3591 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

22 Feb 2018

BRIEF-KPC Pharmaceuticals to invest 10 mln yuan to set up medicine unit in Yichun

* Says it plans to invest 10 million yuan to set up a Yichun-based wholly owned medicine unit

14 Feb 2018

BRIEF-KPC Pharmaceuticals names president

Jan 31KPC Pharmaceuticals Inc * Says it names Zhong Xianggang as president Source text in Chinese: https://goo.gl/RaLKZ4 Further company coverage: (Beijing Headline News)

31 Jan 2018

REFILE-BRIEF-KPC Pharmaceuticals Says President Resigns Due To Personal Reasons

* SAYS PRESIDENT DAI XIAOCHANG RESIGNS DUE TO PERSONAL REASONS Source text in Chinese: http://bit.ly/2C21wh0 Further company coverage: (Reporting by Hong Kong newsroom)

28 Dec 2017

BRIEF-KPC Pharmaceuticals and unit passe review of high-tech enterprise recognition

* Says it and wholly owned Xishuangbanna medical unit passe review of high-tech enterprise recognition, to enjoy a tax preference of 15 percent for three years

19 Dec 2017

Earnings vs. Estimates